Nanocarrier Delivery Repurposes Non-oncologic Drugs for Cancer Therapy, Review Shows

Several FDA-approved drugs like metformin and doxycycline show anticancer effects but poor tumor selectivity. Nanocarrier delivery enhances tumor accumulation, bioavailability, and enables combination therapy, but clinical translation faces regulatory hurdles. (Review; no origin…

• Narrative review summarizing recent progress in repurposing non-oncologic drugs with nanocarriers for cancer treatment.
• Repurposed agents include metformin, celecoxib, itraconazole; nanocarriers target tumor cells, microenvironment, and cancer stem cells.
• Limitation: Most evidence is preclinical, and clinical trials of nanocarrier-enabled repurposed drugs are lacking.

RadPigeon summaries are original and for information only. They are not clinical advice.